...
首页> 外文期刊>Viral immunology >Expression of leukocyte immunoglobulin-like receptors and natural killer receptors on virus-specific CD8+ T cells during the evolution of Epstein-Barr virus-specific immune responses in vivo.
【24h】

Expression of leukocyte immunoglobulin-like receptors and natural killer receptors on virus-specific CD8+ T cells during the evolution of Epstein-Barr virus-specific immune responses in vivo.

机译:在体内Epstein-Barr病毒特异性免疫应答进化过程中,病毒特异性CD8 + T细胞上白细胞免疫球蛋白样受体和自然杀伤受体的表达。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Antigen-primed cytotoxic T lymphocytes (CTL) may express leukocyte immunoglobulin-like receptors (LILRs) and natural killer receptors (NKRs). Published work suggests that expression of some of these receptors confers survival advantage, leading to the idea that cells expressing such receptors may accumulate as an antigen-specific response evolves. Here we tested this hypothesis by analyzing expression of CD85j (also known as LILRB1 or ILT2), KIRs, CD94, and CD161 by Epstein- Barr virus (EBV)-specific CTL during the primary and persistent phases of EBV infection in humans. During primary infection, few EBV-specific CTL expressed these receptors and this proportion was equally low in early persistent infection. Thus, expression of these molecules does not influence capacity to survive downregulation of the primary response. However, in donors persistently infected with EBV for many years, a significantly higher proportion of EBV-specific CTL expressed CD85j and NKRs, suggesting that cells expressing these receptors can accumulate with time. Using FACS analysis, we confirmed, at a single cell level, that expression of CD85j, defined by staining with the antibody VMP55, was associated with reduced capacity of EBV-specific CD8+ T cells to respond to antigen. Thus, in the later stages of persistent infection, protective immunity to EBV may be reduced due to the preferential accumulation of hyporesponsive EBV-specific CD8+ T cells.
机译:抗原致敏的细胞毒性T淋巴细胞(CTL)可能表达白细胞免疫球蛋白样受体(LILR)和自然杀伤受体(NKR)。已发表的工作表明,其中一些受体的表达赋予了生存优势,导致了这样一种想法,即表达这种受体的细胞可能会随着抗原特异性反应的发展而积累。在这里,我们通过在人类EBV感染的主要阶段和持续阶段,通过爱泼斯坦-巴尔病毒(EBV)特异性CTL分析CD85j(也称为LILRB1或ILT2),KIR,CD94和CD161的表达,测试了这一假设。在初次感染期间,几乎没有EBV特异性CTL表达这些受体,并且在早期持续感染中这一比例同样较低。因此,这些分子的表达不影响初级反应的下调存活的能力。但是,在多年被EBV持续感染的供体中,EBV特异性CTL表达CD85j和NKRs的比例明显更高,这表明表达这些受体的细胞会随时间积累。使用FACS分析,我们在单个细胞水平上证实了CD85j的表达(通过用抗体VMP55染色来定义)与EBV特异性CD8 + T细胞对抗原应答的能力降低有关。因此,在持续感染的后期,由于低反应性EBV特异性CD8 + T细胞的优先积累,可能会降低对EBV的保护性免疫。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号